Antibody¶§¹®¿¡ »ý±â´Â background °ÆÁ¤ ¾øÀÌ! CAR-T CellÀ» È®ÀÎÇÏ¼¼¿ä
Fluorescent-Labeled Recombinant Proteins for CAR-T Cells
CAR-T cell therapy is based on the principle that T cells removed from a patient or donor can be genetically engineered to express a specific chimeric antigen receptor (CAR). Once these CAR-T cells are infused back into the patient, the CAR will bind to its specific target antigen on the surface of the patient's tumor cells, activating the T cells, and allowing them to attack and destroy the tumor cells.
¢º ½ÇÇè ½Ã°£ ´ÜÃà
¢º Antibody¿¡ ÀÇÇÑ background staining Çö»ó x
¢º CAR-T Cell ÀÌ¿ëÇÑ QC Test ÁøÇà
¢º Unconjugated protein°ú µ¿ÀÏÇÑ binding activity
Detection of CD19-CAR-T Cells with Recombinant Human CD19 Fc Chimera Atto 647N Protein. CD4+CD8+ T cells were either (A) transduced with a hCD19-CAR or (B) not transduced, and then cultured for 11 days. Cells were stained with a PE-Cy7-CD4 and Recombinant Human CD19 Fc Chimera Atto 647N Protein (Catalog # ATM9269), and detected by flow cytometry.
Fluorescent-labeled Proteins to Detect CAR-T Cells
Alexa Fluor SARS-CoV-2 Spike Proteins